Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-01-2008 | Original Article

[¹¹C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy

Authors: Sven N. Reske, Norbert M. Blumstein, Gerhard Glatting

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 1/2008

Abstract

Purpose

The aim of this study was to assess the accuracy and clinical impact of [¹¹C]choline PET/CT for localizing occult relapse of prostate adenocarcinoma after radical prostatectomy.

Methods

Fourty-nine patients with prostate adenocarcinoma, radical prostatectomy, no evidence of metastatic disease, and occult relapse underwent [¹¹C]choline PET/CT. Thirty-six of the patients had biochemical evidence and histological evaluation of local recurrence. Thirteen patients had PSA < 0.3 ng/ml and no evidence of active disease after 1 year follow-up. Focal nodular [¹¹C]choline uptake in the prostatic fossa was visually assessed and graded on a five point scale. Maximum standardized radioactivity uptake value (SUV_max) and the lesion size were measured. A receiver operating characteristic (ROC) analysis was performed and the clinical impact of the PET/CT study was determined.

Results

[¹¹C]choline PET/CT was true positive in 23/33 patients and true negative in 12/13 controls. SUV_max of local recurrence was 3.0 (median, range 0.6–7.4) and 1.1 (0.4–1.6) in controls (p = 0.0002). Lesion size was 1.7 cm (range 0.9–3.7). Area under the ROC curve for detecting relapse was 0.90 ± 0.05 and 0.83 ± 0.06 for visual evaluation and SUV_max, respectively. Sensitivity and specificity of [¹¹C]choline PET/CT were 0.73 and 0.88, respectively. [¹¹C]choline PET/CT identified 12/17 (71%) patients with a favourable biochemical response to local radiotherapy at 2 year (median, 0.8–3.2 range) follow-up.

Conclusions

Focally increased [¹¹C]choline uptake in the prostatic bed reliably predicted local low volume occult relapsing prostate adenocarcinoma after radical prostatectomy and identified 71% of patients with a favourable biochemical response to local radiotherapy.

Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2005. CA Cancer J Clin 2005;53:5–26.CrossRef

Hricak H, Schoder H, Pucar D, Lis E, Eberhardt SC, Onyebuchi CN, et al. Advances in imaging in the postoperative patient with a rising prostate-specific antigen level. Semin Oncol 2003;30:616–34.PubMedCrossRef

Bott SR. Management of recurrent disease after radical prostatectomy. Prostate Cancer Prostatic Dis 2004;7:211–6.PubMedCrossRef

Fowler FJJ, Barry MJ, Lu-Yao G, Roman A, Wasson J, Wennberg JE. Patient-reported complications and follow-up treatment after radical prostatectomy. The National Medicare Experience: 1988–1990 (updated June 1993). Urology 1993;42:622–9.PubMedCrossRef

Lu-Yao GL, Potosky AL, Albertsen PC, Wasson JH, Barry MJ, Wennberg JE. Follow-up prostate cancer treatments after radical prostatectomy: a population-based study. J Natl Cancer Inst 1996;88:166–73.PubMedCrossRef

Boccon-Gibod L, Djavan WB, Hammerer P, Hoeltl W, Kattan MW, Prayer-Galetti T, et al. Management of prostate-specific antigen relapse in prostate cancer: a European consensus. Int J Clin Pract 2004;58:382–90.PubMedCrossRef

Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am 1997;24:395–406.PubMedCrossRef

Cox JD, Gallagher MJ, Hammond EH, Kaplan RS, Schellhammer PF. Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. J Clin Oncol 1999;17:1155–63.PubMed

Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591–7.PubMedCrossRef

10.

Connolly JA, Shinohara K, Presti JCJ, Carroll PR. Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins. Urology 1996;47:225–31.PubMedCrossRef

11.

Shekarriz B, Upadhyay J, Wood DPJ, Hinman J, Raasch J, Cummings GD, et al. Vesicourethral anastomosis biopsy after radical prostatectomy: predictive value of prostate-specific antigen and pathologic stage. Urology 1999;54:1044–8.PubMedCrossRef

12.

Saleem MD, Sanders H, Abu El Naser M, El-Galley R. Factors predicting cancer detection in biopsy of the prostatic fossa after radical prostatectomy. Urology 1998;51:283–6.PubMedCrossRef

13.

Scattoni V, Roscigno M, Raber M, Montorsi F, Da Pozzo L, Guazzoni G, et al. Multiple vesico-urethral biopsies following radical prostatectomy: the predictive roles of TRUS, DRE, PSA and the pathological stage. Eur Urol 2003;44:407–14.PubMedCrossRef

14.

Cher ML, Bianco FJJ, Lam JS, Davis LP, Grignon DJ, Sakr WA, et al. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol 1998;160:1387–91.PubMedCrossRef

15.

Rodriguez-González A, Molina AR, Benitez-Rajal J, Lacal JC. Phospholipase D and choline kinase: their role in cancer development and their potential as drug targets. Prog Cell Cycle Res 2003;5:191–201.PubMed

16.

Ackerstaff E, Glunde K, Bhujwalla ZM. Choline phospholipid metabolism: a target in cancer cells? J Cell Biochem 2003;90:525–33.PubMedCrossRef

17.

Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 1998;39:990–5.PubMed

18.

Reske SN, Blumstein NM, Neumaier B, Gottfried HW, Finsterbusch F, Kocot D, et al. Imaging prostate cancer with ¹¹C-Choline PET/CT. J Nucl Med 2006;47:1249–54.PubMed

19.

de Jong I, Pruim J, Elsinga P, Vaalburg W, Mensink H. Visualization of prostate cancer with ¹¹C-choline positron emission tomography. Eur Urol 2002;42:18–23.PubMedCrossRef

20.

Kotzerke J, Prang J, Neumaier B, Volkmer B, Guhlmann A, Kleinschmidt K, et al. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med 2000;27:1415–9.PubMedCrossRef

21.

Picchio M, Messa C, Landoni C, Gianolli L, Sironi S, Brioschi M, et al. Value of [¹¹C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [¹⁸F]fluorodeoxyglucose-positron emission tomography. J Urol 2003;169:1337–40.PubMedCrossRef

22.

Schmid DT, John H, Zweifel R, Cservenyak T, Westera G, Goerres GW, et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology 2005;235:623–8.PubMedCrossRef

23.

Yoshida S, Nakagomi K, Goto S, Futatsubashi M, Torizuk T. ¹¹C-choline positron emission tomography in prostate cancer: primary staging and recurrent site staging. Urol Int 2005;74:214–20.PubMedCrossRef

24.

Kotzerke J, Volkmer BG, Glatting G, van-den-Hoff J, Gschwend JE, Messer P, et al. Intraindividual comparison of [¹¹C]acetate and [¹¹C]choline PET for detection of metastases of prostate cancer. Nuklearmedizin 2003;42:25–30.PubMed

25.

Wittekind C, Meyer H, Bootz F. TNM- Klassifikation maligner Tumoren. 6th ed. Berlin Heidelberg New York: Springer; 2003.

26.

Wilson AA, Garcia G, Jin L, Houle S. Radiotracer synthesis from [¹¹C]-iodomethane: a remarkably simple captive solvent method. Nucl Med Biol 2000;27:529–32.PubMedCrossRef

27.

Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology 1993;189:847–50.PubMed

28.

Metz CE. ROC methodology in radiologic imaging. Invest Radiol 1986;21:720–33.PubMedCrossRef

29.

Stephenson AJ, Shariat SF, Zelefsky MJ, Kattan MW, Butler EB, Teh BS, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 2004;291:1325–32.PubMedCrossRef

30.

Kotzerke J, Volkmer BG, Neumaier B, Gschwend JE, Hautmann RE, Reske SN. Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2002;29:1380–94.PubMedCrossRef

31.

Hara T. ¹⁸F-fluorocholine: a new oncologic PET tracer. J Nucl Med 2001;42:1815–7.PubMed

32.

DeGrado TR, Baldwin SW, Wang S, Orr MD, Liao RP, Friedman HS, et al. Synthesis and evaluation of ¹⁸F-labeled choline analogs as oncologic PET tracers. J Nucl Med 2001;42:1805–14.PubMed

33.

Oyama N, Miller TR, Dehdashti F, Siegel BA, Fischer KC, Michalski JM, et al. ¹¹C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med 2003;44:549–55.PubMed

34.

Cimitan M, Bortolus R, Morassut S, Canzonieri V, Garbeglio A, Baresic T, et al. [¹⁸F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 2006;33:1387–98.PubMedCrossRef

35.

Wachter S, Tomek S, Kurtaran A, Wachter-Gerstner N, Djavan B, Becherer A, et al. ¹¹C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer. J Clin Oncol 2006;24:2513–9.PubMedCrossRef

36.

Reske SN, Blumstein NM, Glatting G. PET and PET/CT in relapsing prostate carcinoma. Urologe A 2006;45:1240–50.PubMedCrossRef

37.

Sella T, Schwartz LH, Swindle PW, Onyebuchi CN, Scardino PT, Scher HI, et al. Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology 2004;231:379–85.PubMedCrossRef

Title: [11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy
Authors: Sven N. Reske
Norbert M. Blumstein
Gerhard Glatting
Publication date: 01-01-2008
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 1/2008
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-007-0530-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

[¹¹C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2008

Activity-based costing evaluation of [18F]-fludeoxyglucose production

In vivo amyloid imaging with PET in frontotemporal dementia

Localization of parathyroid enlargement: dual-tracer subtraction technique and double-phase 99mTc-MIBI scintigraphy are complementary procedures

Tumor hypoxia imaging in orthotopic liver tumors and peritoneal metastasis: a comparative study featuring dynamic 18F-MISO and 124I-IAZG PET in the same study cohort

Avid uptake of [18F]-FDG in fibrous dysplasia can mimic skeletal involvement in Hodgkin’s disease

Metabolic–dopaminergic mapping of the 6-hydroxydopamine rat model for Parkinson’s disease